Research into the mechanisms and manifestations of solid tumor vascularization was
launched more than 50 years ago with the proposition and experimental demonstrations that …

Colorectal cancer (CRC) is a serious public health issue, and it has the leading incidence
and mortality among malignant tumors worldwide. CRC patients with metastasis in the liver …

Vessel co-option has been demonstrated to mediate colorectal cancer liver metastasis
(CRCLM) resistance to antiangiogenic therapy. The current mechanisms underlying vessel …

Runt-related transcription factor 1 (RUNX1) is frequently involved in the progression of acute
leukemia. However, emerging and discoverable RUNX1 somatic mutations, RUNX1 …

The first consensus guidelines for scoring the histopathological growth patterns (HGPs) of
liver metastases were established in 2017. Since then, numerous studies have applied …

Background Colorectal cancer liver metastases (CRCLM) are associated with a poor
prognosis, reflected by a five-year survival rate of 14%. Anti-angiogenic therapy through anti …

Tumor vessel co-option (VCO) is a non-angiogenic vascularization mechanism that is a
possible cause of resistance to anti-angiogenic therapy (AAT). Multiple tumors are …

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, with 20%
of patients presenting with metastatic disease at diagnosis. TGF-β signaling plays a crucial …

Abstract The actin 2/3 complex (Arp2/3) regulates actin polymerization and nucleation of
actin filaments, is associated with cell motility, and has been shown to play a key role in the …

The liver is the most common metastatic site in colorectal cancer (CRC) patients. Indeed, 25–
30% of the cases develop colorectal liver metastasis (CLM), showing an extremely poor 5 …